Abstract: An octapeptide inhibitor of myristoylating enzymes is disclosed having an amino acid sequence as follows or a physiologically acceptable amide or salt derivative thereof: ##STR1##

Abstract: An octapeptide inhibitor of myristoylating enzymes is disclosed having an amino acid sequence as follows or a physiologically acceptable amide or salt derivative thereof: ##STR1##

Abstract: A cDNA having a base sequence for human skin fibroblast collagenase has been cloned and characterized and the amino acid sequence of the human skin fibroblast protein has been determined.

Abstract: Human soluble immune response suppressor (SIRS) having a molecular weight of about 10,000 to 15,000, an isoelectric point of about 7 and a defined amino acid composition distinctly different from murine SIRS is produced from a culture of MOLT-4 cells.

Abstract: A resin and method for using the resin for solid phase peptide synthesis. The resin has a sulfoxide linkage, which is stable to strong acid conditions. The sulfoxide linkage can be reduced to a sulfide linkage, which allows cleavage of the peptide from the resin under mild acid conditions.

Abstract: A resin and method for preparing the resin for solid phase peptide synthesis. The resin has a sulfoxide linkage, which is stable to strong acid conditions. The sulfoxide linkage can be reduced to a sulfide linkage, which allows cleavage of the peptide from the resin under mild acid conditions.

Abstract: A process for the preparation of substituted aromatic amines comprising (1) contacting a primary aromatic amine with an oxidizing agent in a homogeneous solution containing water, an oxidizable water-miscible organic solvent and a base, and (2) reducing the solution with a reducing agent to produce the substituted aromatic amine.

Abstract: A method is disclosed for stimulating the immune system of a warm-blooded animal by the production of antibodies by administering an effective amount of Cytophaga allerginae lipopolysaccharide endotoxin.

Abstract: This invention discloses the use of marker genes which do not involve antibiotics for environmental tracking of microorganisms. Such marker genes include chromogenic marker genes, and marker genes that allow a cell to proliferate on media containing a sole nutrient source which cannot be utilized by untransformed cells. Genetic transformation using such marker genes is used to create cells with two or more phenotypic traits that do not coexist in natural, untransformed cells. As one example, pseudonomad cells have been transformed with beta-galactosidase and lactose permease genes, to create cells which are (1) fluorescent, (2) able to hydrolyze X-gal or ONPG, and (3) capable of proliferation on lactose as a sole carbon source. Such cells are useful as soil inoculants, and their descendants can be tracked by using these characteristics. The marker genes may be placed under the control of inducible promoters.

Abstract: A method for the production of collagenase inducing factor is disclosed which comprises growing the human liver adenocarcinoma cell line SK-HEP-1 in nutrient culture medium at 35.degree.-38.degree. C. and recovering the resulting collagenase inducing factor from the spent cells or conditioned medium.

Abstract: Glycosylated plasminogen activator (t-PA) having a glycosylation pattern significantly different than exhibited by t-PA from Bowes melanoma cells is obtained from cultured normal human colon fibroblast cells (CCD-18Co).

Abstract: Preparation of sorbic acid from precursors by contact with acid catalysts is improved by utilizing crystallization to separate sorbic acid during the preparation.

Abstract: A peptide substrate for myristoylating enzymes is disclosed having an amino acid sequence selected from the group consisting of the following sequences or a physiologically acceptable amide or salt derivative thereof: ##STR1## wherein R=Ala, Asn, Gln or Ser;S=Ala, Arg, Gln, Glu, Phe or Ser;T=Ala or Lys;W=Ala or Ser;X=Ala, Tyr, or Lys;Y=Arg or Pro; andZ=Arg, Leu or Lys.

Abstract: A method of prolonging or enhancing the bioactivity of atrial peptides is disclosed in which thiorphan or kelatorphan is administered contemporaneously with the administration of the atrial peptide.

Abstract: Butadiene and acetic acid are reacted with metal ion oxidant to prepare acetoxyhexenoic acids which are then converted to sorbic acid.

Abstract: A preparative scale method for the isolation of unreduced oligosaccharides of glycoproteins and glycohormone having a N-linked oligosaccharide structure is disclosed. The method employs hydrazinolysis of the glycoprotein or glycohormone under reaction conditions to cause cleavage at the N-linked sites, producing a mixture having as a major component a de-N-acetylated hydrazone derivative of the oligosaccharides, followed by N-acylation of the hydrazone derivative, acid-catalysis of the hydrazone derivative to produce unreduced oligosaccharides, and subjecting the resulting unreduced oligosaccharides to cellulose column chromatography to remove contaminants and to recover the unreduced oligosaccharides.

Abstract: Novel peptide hydroxamic acid derivatives having useful collagenase inhibitory activity and capable of forming affinity resins for the purification of vertebrate collagenase are defined by the following structural formula:R--Pro--Leu--Gly--NHOHwherein R=H or N-protecting group or agarose.

Abstract: A preparative scale method for the isolation of unreduced oligosaccharides of glycoproteins and glycohormones having an N-linked oligosaccharide structure is disclosed. The method employs hydrazinolysis of the glycoprotein or glycohormone under reaction conditions to cause cleavage at the N-linked sites, producing a mixture having as a major component a de-N-acetylated hydrazone derivative of the oligosaccharides, followed by N-acylation of the hydrazone derivative, acid-catalysis of the hydrazone derivative to produce unreduced oligosaccharides, and subjecting the resulting unreduced oligosaccharides to cellulose column chromatography to remove contaminants and to recover the unreduced oligosaccharides.

Abstract: Novel synthetic atrial peptides are provided with enhanced natriuretic properties by substituting one or two arginine residues for the N-terminal ser-ser in atriopeptins I, II and III and their physiologically acceptable salts, esters and amides.

Abstract: An octapeptide inhibitor of myristoylating enzymes is disclosed having an amino acid sequence selected from the group consisting of the following sequences or a physiologically acceptable amide or salt derivative thereof: ##STR1## wherein R=Leu, Phe, Tyr or Val.